|drug2699||Public Health England Gold Standard Wiki||1.00|
|drug3756||Zinc gluconate Wiki||1.00|
|drug2938||SAMBA II (Diagnostic for the Real World) Wiki||1.00|
|D000208||Acute Disease NIH||0.71|
|D014777||Virus Diseases NIH||0.11|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
Mortality from Covid-19 increases with age, reaching 14.8% from the age of 80. The severity of the infection is linked to the acute respiratory distress syndrome (ARDS) which requires intensive care. ARDS is the consequence of the reactional inflammatory storm that damages the lungs. Aged subjects are particularly prone to zinc and vitamin D deficiency. These two micronutrients are able to modulate the immune response by reducing the inflammatory storm. The hypothesis is that supplementation with zinc and vitamin D would reduce the inflammatory reaction which worsens ARDS and leads to the death of subjects infected with Covid-19.
Description: symptomatic subjects and asymptomatic subjectsMeasure: Survival rate in overall subjects Time: Two months after inclusion
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports